Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

47.70 -1.12 (-2.29%)
Streaming Delayed Price Updated: 2:43 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,478
Open 49.00
Bid (Size) 47.43 (100)
Ask (Size) 47.73 (700)
Prev. Close 48.82
Today's Range 46.76 - 49.50
52wk Range 13.86 - 48.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid a year of exceptional stock appreciation. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+69.7%
+69.7%
1 Month
+17.5%
+17.5%
3 Month
+28.1%
+28.1%
6 Month
+68.8%
+68.8%
1 Year
+234.0%
+234.0%

More News

Read More
News headline image
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗
Via Chartmill
News headline image
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
Via Chartmill
Topics Earnings
News headline image
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
What is the current price of Rapport Therapeutics, Inc. - Common Stock?
The current price of Rapport Therapeutics, Inc. - Common Stock is 47.70
When was Rapport Therapeutics, Inc. - Common Stock last traded?
The last trade of Rapport Therapeutics, Inc. - Common Stock was at 08/12/26 02:43 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.